Cargando…

Efficacy and risk of mRNA vaccination in patients with autoimmune inflammatory rheumatic diseases

Coronavirus disease 2019 (COVID-19), which spread worldwide from Wuhan, China, in 2019, appeared for a time to be overcome by the remarkable efficacy of mRNA vaccines; however, new variants of severe acute respiratory syndrome coronavirus 2 have emerged and remain rampant. The involvement of the vir...

Descripción completa

Detalles Bibliográficos
Autores principales:	Kato, Yasuhiro, Morita, Takayoshi, Kumanogoh, Atsushi
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2023
Materias:	Review
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9816539/ https://www.ncbi.nlm.nih.gov/pubmed/36609472 http://dx.doi.org/10.1186/s41232-022-00247-1

Ejemplares similares

Persistence of SARS-CoV-2 neutralizing antibodies and anti-Omicron IgG induced by BNT162b2 mRNA vaccine in patients with autoimmune inflammatory rheumatic disease: an explanatory study in Japan
por: Yamaguchi, Yuta, et al.
Publicado: (2022)

Marked increase of interferon-β after BNT162b2 mRNA vaccination: a case of polyarthritis with pleurisy
por: Shimagami, Hiroshi, et al.
Publicado: (2022)

Myocarditis and pericarditis following mRNA vaccination in autoimmune inflammatory rheumatic disease patients: A single‐center experience
por: Patel, Shreeya, et al.
Publicado: (2022)

Efficacy and safety of mRNA and AstraZeneca COVID-19 vaccines in patients with autoimmune rheumatic diseases: A systematic review
por: Joudeh, Anwar I., et al.
Publicado: (2023)

Vaccinations in autoimmune inflammatory rheumatic diseases
por: Szenborn, Leszek
Publicado: (2016)

Post-mRNA vaccine flares in autoimmune inflammatory rheumatic diseases: Results from the COronavirus National Vaccine registry for ImmuNe diseases SINGapore (CONVIN-SING)
por: Ma, Margaret, et al.
Publicado: (2023)

Immunogenicity and safety of the mRNA-based BNT162b2 vaccine in systemic autoimmune rheumatic diseases patients
por: Pri-Paz Basson, Yael, et al.
Publicado: (2022)

Autoimmune Rheumatic Disease Flares with Myocarditis Following COVID-19 mRNA Vaccination: A Case-Based Review
por: Lai, Yi Wye, et al.
Publicado: (2022)

Predictors of Immunogenic Response to the BNT162b2 mRNA COVID-19 Vaccination in Patients with Autoimmune Inflammatory Rheumatic Diseases Treated with Rituximab
por: Furer, Victoria, et al.
Publicado: (2022)

mRNA vaccine shows promise in autoimmunity
por: Flemming, Alexandra
Publicado: (2021)

Therapeutic efficacy of denosumab for rheumatoid arthritis: a systematic review and meta-analysis
por: Yagita, Mayu, et al.
Publicado: (2021)

The Risk of Autoimmunity Development following mRNA COVID-19 Vaccination
por: Świerkot, Jerzy, et al.
Publicado: (2022)

Consecutive BNT162b2 mRNA vaccination induces short-term epigenetic memory in innate immune cells
por: Yamaguchi, Yuta, et al.
Publicado: (2022)

The therapeutic efficacy of denosumab for the loss of bone mineral density in glucocorticoid-induced osteoporosis: a meta-analysis
por: Yamaguchi, Yuta, et al.
Publicado: (2020)

Autoimmune inflammatory rheumatic diseases post-COVID‐19 vaccination
por: Safary, Azam, et al.
Publicado: (2022)

Vaccination of patients with autoimmune inflammatory rheumatic disease: physicians’ perspectives
por: Moon, Ki Won
Publicado: (2023)

Dose-Dependent Impairment of the Immune Response to the Moderna-1273 mRNA Vaccine by Mycophenolate Mofetil in Patients with Rheumatic and Autoimmune Liver Diseases
por: De Santis, Maria, et al.
Publicado: (2022)

Efficacy of mycophenolate mofetil as a remission induction therapy in antineutrophil cytoplasmic antibody-associated vasculitis—a meta-analysis
por: Kuzuya, Kentaro, et al.
Publicado: (2020)

A Tolerizing mRNA Vaccine against Autoimmunity?
por: Furlan, Roberto
Publicado: (2021)

Type of mRNA COVID-19 vaccine and immunomodulatory treatment influence humoral immunogenicity in patients with inflammatory rheumatic diseases
por: Raptis, Catherine E., et al.
Publicado: (2022)

The COVID‐19 vaccine: Attitudes and vaccination in patients with autoimmune inflammatory rheumatic diseases
por: Chen, Jiali, et al.
Publicado: (2022)

Duration of SARS-CoV-2 RNA positivity from various specimens and clinical characteristics in patients with COVID-19: a systematic review and meta-analysis
por: Okita, Yasutaka, et al.
Publicado: (2022)

The Practice Guideline for Vaccinating Korean Patients with Autoimmune Inflammatory Rheumatic Disease
por: Seo, Yu Bin, et al.
Publicado: (2020)

Immune responses to mRNA vaccines against SARS-CoV-2 in patients with immune-mediated inflammatory rheumatic diseases
por: Sieiro Santos, Cristiana, et al.
Publicado: (2022)

Autoimmune Hemolytic Anemia After mRNA COVID Vaccine
por: Fatima, Zainab, et al.
Publicado: (2022)

Correction: Immunogenicity and safety of the BNT162b2 mRNA COVID-19 vaccine in adult patients with autoimmune inflammatory rheumatic diseases and in the general population: a multicentre study
Publicado: (2022)

Pneumococcal vaccination in autoimmune rheumatic diseases
por: Rákóczi, Éva, et al.
Publicado: (2017)

Steroid treatment suppresses the CD4(+) T-cell response to the third dose of mRNA COVID-19 vaccine in systemic autoimmune rheumatic disease patients
por: Maliah, Avishai, et al.
Publicado: (2022)

Role of inflammasomes in inflammatory autoimmune rheumatic diseases
por: Yi, Young-Su
Publicado: (2018)

Immunogenicity of inactivated COVID-19 vaccine in patients with autoimmune inflammatory rheumatic diseases
por: Zheng, Yi-Qing, et al.
Publicado: (2022)

Vaccines in adults with autoimmune inflammatory rheumatic disease: What are the knowledge and attitudes of physicians?
por: Badak, Suade Özlem
Publicado: (2022)

Efficacy of COVID-19 mRNA vaccination in patients with autoimmune disorders: humoral and cellular immune response
por: Filippini, Federica, et al.
Publicado: (2023)

Breakthrough infection after three doses of COVID-19 mRNA vaccine in systemic autoimmune rheumatic diseases: two cases in patients on TNF inhibitor monotherapy
por: Vanni, Kathleen MM, et al.
Publicado: (2022)

Antibody kinetics in patients with rheumatic diseases after SARS-CoV-2 mRNA vaccination
por: Frey, Sarah, et al.
Publicado: (2021)

Point of view on the vaccination against COVID-19 in patients with autoimmune inflammatory rheumatic diseases
por: Furer, Victoria, et al.
Publicado: (2021)

Influenza, Pneumococcal and Herpes Zoster Vaccination Rates in Patients with Autoimmune Inflammatory Rheumatic Diseases
por: Krasselt, Marco, et al.
Publicado: (2023)

Immunogenicity against the BNT162b2 mRNA COVID-19 Vaccine in Rheumatic Disease Patients Receiving Immunosuppressive Therapy
por: Sugihara, Koichi, et al.
Publicado: (2022)

Safety and Immunogenicity Following the Second and Third Doses of the BNT162b2 mRNA COVID-19 Vaccine in Adolescents with Juvenile-Onset Autoimmune Inflammatory Rheumatic Diseases: A Prospective Multicentre Study
por: Heshin-Bekenstein, Merav, et al.
Publicado: (2023)

The mRNA COVID-19 vaccine – A rare trigger of autoimmune hepatitis?
por: McShane, Cathy, et al.
Publicado: (2021)

Longer Prehospitalization and Preintubation Periods in Intubated Non-survivors and ECMO Patients With COVID-19: A Systematic Review and Meta-Analysis
por: Funakoshi, Kenji, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_dtn72nt1ugfqvaslmcjaf4nfll